Global Hunter Securities Starts MediciNova (MNOV) at Speculative Buy; Undervalued Opportunity but Uncertainties Lie Ahead
Tweet Send to a FriendGet Alerts MNOV Hot Sheet
Price: $3.37 +31.13%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade MNOV Now!
Global Hunter Securities initiates coverage on MediciNova (NASDAQ: MNOV) with a Speculative Buy. PT $4.
Global analyst said, "We view MN-221, the company’s lead candidate and value driver, as a promising IV therapy in patients with severe exacerbations of asthma and chronic obstructive pulmonary disease (COPD) based on early efficacy and safety data. We believe MN-221’s potential lack of cardiac safety events due to its greater β2-adrenergic receptor selectivity differentiates itself from other existing β2-agonists. Feedback from pulmonologists, critical care specialists and ER physicians indicate, however, that it is premature to rule out cardiac events for MN-221, given that the drug has not been tested in a significant number of patients. We believe the Phase IIb and Phase III studies should help mitigate this concern."
For more ratings news on MediciNova click here and for the rating history of MediciNova click here.
Shares of MediciNova closed at $2.34 yesterday, with a 52 week range of $1.94-$6.40.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Global analyst said, "We view MN-221, the company’s lead candidate and value driver, as a promising IV therapy in patients with severe exacerbations of asthma and chronic obstructive pulmonary disease (COPD) based on early efficacy and safety data. We believe MN-221’s potential lack of cardiac safety events due to its greater β2-adrenergic receptor selectivity differentiates itself from other existing β2-agonists. Feedback from pulmonologists, critical care specialists and ER physicians indicate, however, that it is premature to rule out cardiac events for MN-221, given that the drug has not been tested in a significant number of patients. We believe the Phase IIb and Phase III studies should help mitigate this concern."
For more ratings news on MediciNova click here and for the rating history of MediciNova click here.
Shares of MediciNova closed at $2.34 yesterday, with a 52 week range of $1.94-$6.40.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Maxim Group Starts Agenus (AGEN) at Buy, PT $19
- Credit Suisse Starts Coca-Cola (KO) at Outperform
Create E-mail Alert Related Categories
New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
